Global Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Research Report 2023

Publication ID:

PB504238028

Publication Date:

April 5, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Highlights
The global Chronic Obstructive Pulmonary Disorder (COPD) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Chronic Obstructive Pulmonary Disorder (COPD) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Chronic Obstructive Pulmonary Disorder (COPD) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Chronic Obstructive Pulmonary Disorder (COPD) in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Chronic Obstructive Pulmonary Disorder (COPD) include GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma and Roche, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disorder (COPD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Disorder (COPD).
The Chronic Obstructive Pulmonary Disorder (COPD) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Chronic Obstructive Pulmonary Disorder (COPD) market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Obstructive Pulmonary Disorder (COPD) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma
Segment by Type
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Disorder (COPD) companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Short-Acting Bronchodilators
1.2.3 Corticosteroids
1.2.4 Methylxanthines
1.2.5 Long-Acting Bronchodilators
1.2.6 Phosphodiesterase-4 Inhibitors
1.2.7 Others
1.3 麻豆原创 by Application
1.3.1 Global Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Perspective (2018-2029)
2.2 Chronic Obstructive Pulmonary Disorder (COPD) Growth Trends by Region
2.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Chronic Obstructive Pulmonary Disorder (COPD) Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Chronic Obstructive Pulmonary Disorder (COPD) Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Dynamics
2.3.1 Chronic Obstructive Pulmonary Disorder (COPD) Industry Trends
2.3.2 Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Drivers
2.3.3 Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Challenges
2.3.4 Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue
3.1.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue (2018-2023)
3.1.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder (COPD) Revenue
3.4 Global Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Concentration Ratio
3.4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2022
3.5 Chronic Obstructive Pulmonary Disorder (COPD) Key Players Head office and Area Served
3.6 Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service
3.7 Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Type
4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted 麻豆原创 Size by Type (2024-2029)
5 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Application
5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size (2018-2029)
6.2 North America Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Country (2018-2023)
6.4 North America Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size (2018-2029)
7.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Country (2018-2023)
7.4 Europe Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size (2018-2029)
9.2 Latin America Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.1.5 GSK Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.2.5 Pfizer Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.3.5 Merck Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.4.5 Novartis Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.5.5 AstraZeneca Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Detail
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Teva Pharmaceuticals
11.7.1 Teva Pharmaceuticals Company Detail
11.7.2 Teva Pharmaceuticals Business Overview
11.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.7.5 Teva Pharmaceuticals Recent Development
11.8 Ario Pharma
11.8.1 Ario Pharma Company Detail
11.8.2 Ario Pharma Business Overview
11.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.8.5 Ario Pharma Recent Development
11.9 Roche
11.9.1 Roche Company Detail
11.9.2 Roche Business Overview
11.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.9.5 Roche Recent Development
11.10 Ache
11.10.1 Ache Company Detail
11.10.2 Ache Business Overview
11.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.10.5 Ache Recent Development
11.11 Almirall
11.11.1 Almirall Company Detail
11.11.2 Almirall Business Overview
11.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.11.5 Almirall Recent Development
11.12 Aquinox Pharmaceuticals
11.12.1 Aquinox Pharmaceuticals Company Detail
11.12.2 Aquinox Pharmaceuticals Business Overview
11.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.12.5 Aquinox Pharmaceuticals Recent Development
11.13 Asmacure
11.13.1 Asmacure Company Detail
11.13.2 Asmacure Business Overview
11.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.13.5 Asmacure Recent Development
11.14 Astellas Pharma
11.14.1 Astellas Pharma Company Detail
11.14.2 Astellas Pharma Business Overview
11.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.14.5 Astellas Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.